Factors Impacting Efficacy of AAV-Mediated CRISPR-Based Genome Editing for Treatment of Choroidal Neovascularization

Molecular Therapy. Methods & Clinical Development
Sook Hyun ChungGlenn Yiu

Abstract

Frequent injections of anti-vascular endothelial growth factor (anti-VEGF) agents are a clinical burden for patients with neovascular age-related macular degeneration (AMD). Genomic disruption of VEGF-A using adeno-associated viral (AAV) delivery of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 has the potential to permanently suppress aberrant angiogenesis, but the factors that determine the optimal efficacy are unknown. Here, we investigate two widely used Cas9 endonucleases, SpCas9 and SaCas9, and evaluate the relative contribution of AAV-delivery efficiency and genome-editing rates in vivo to determine the mechanisms that drive successful CRISPR-based suppression of VEGF-A, using a mouse model of laser-induced choroidal neovascularization (CNV). We found that SpCas9 demonstrated higher genome-editing rates, greater VEGF reduction, and more effective CNV suppression than SaCas9, despite similar AAV transduction efficiency between a dual-vector approach for SpCas9 and single-vector system for SaCas9 to deliver the Cas9 orthologs and single guide RNAs (gRNAs). Our results suggest that successful VEGF knockdown using AAV-mediated CRISPR systems may be determined more by the efficiency of genome editing...Continue Reading

References

Dec 1, 1995·Archives of Ophthalmology·L P AielloM A Iwamoto
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·E A PierceL E Smith
Mar 26, 2003·Journal of Cellular Physiology·Yoshitsugu SaishinPeter A Campochiaro
Jun 27, 2006·Investigative Ophthalmology & Visual Science·Magali Saint-GeniezPatricia A D'Amore
Oct 25, 2006·International Ophthalmology Clinics·Pravin U Dugel
May 18, 2011·Nucleic Acids Research·Kensuke NakamuraShigehiko Kanaya
Jun 24, 2011·Science Translational Medicine·Luk H VandenbergheJean Bennett
Oct 25, 2012·The Journal of Clinical Investigation·Toshihide KuriharaMartin Friedlander
Nov 15, 2012·Methods in Molecular Biology·John G Flannery, Meike Visel
Mar 16, 2013·Current Eye Research·Tsutomu IgarashiHiroshi Takahashi
Oct 3, 2013·Ophthalmology·Juan E GrunwaldUNKNOWN CATT Research Group
Jan 16, 2014·Investigative Ophthalmology & Visual Science·Yanchao JiangM Elizabeth Hartnett
Mar 4, 2014·Expert Review of Clinical Pharmacology·Bozho TodorichPaul Hahn
Jun 22, 2014·American Journal of Ophthalmology·Glenn YiuTamer H Mahmoud
Dec 17, 2014·Nature Biotechnology·Shengdar Q TsaiJ Keith Joung
Dec 30, 2014·Ophthalmology·Juan E GrunwaldUNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials Research Group
Apr 2, 2015·Nature·F Ann RanFeng Zhang
Jun 10, 2016·Nature Protocols·Rosario Fernandez-GodinoEric A Pierce
Jul 2, 2016·Investigative Ophthalmology & Visual Science·Sandy S C HungAlex W Hewitt
Sep 7, 2016·Nature Methods·Wei Leong ChewGeorge M Church
Oct 22, 2016·Investigative Ophthalmology & Visual Science·Glenn YiuZeljka Smit-McBride
Feb 22, 2017·Nature Communications·Eunji KimJin-Soo Kim
Feb 28, 2017·Investigative Ophthalmology & Visual Science·Xionggao HuangHetian Lei
Apr 4, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chaoran YinWenhui Hu
Jul 26, 2017·Nature Communications·Xionggao HuangHetian Lei
Nov 9, 2017·Investigative Ophthalmology & Visual Science·Immanuel P SeitzUNKNOWN RD-CURE Consortium
Dec 17, 2017·Molecular Therapy. Nucleic Acids·Andreas HolmgaardThomas J Corydon
Dec 12, 2018·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ruslan GrishaninMehdi Gasmi
Nov 22, 2019·Current Diabetes Reports·Michael Patrick EllisGlenn Yiu

❮ Previous
Next ❯

Citations

Aug 25, 2020·The CRISPR Journal·Lavina Sierra TayPrashant Mali
Feb 18, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Xiangjun HeBo Feng
Mar 9, 2021·Biomedical Optics Express·Michael SommerspergerNassir Navab
Jun 1, 2021·Molecular Biotechnology·Seyed Ahmad Rasoulinejad, Faezeh Maroufi
Jun 4, 2021·The AAPS Journal·Amanda Catalina Ramirez-Phillips, Dexi Liu
Aug 28, 2021·Biomolecules·Elena PiotterRobert E MacLaren

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence-activated cell sorting
ELISA
pharmacotherapies
GUIDE-seq
FACS
transfection
Flow Cytometry
Assay
PCR
electrophoresis

Software Mentioned

Fiji
GUIDE
DISCOVER

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

Biophysics of CRISPR

This feed focuses on broad characteristics of the CRISPR system and the proteins associated with it.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.